Renishaw posts record full-year revenue, sees steady growth ahead

Renishaw (LON:RSW) reported record FY25 revenue of £713m (+3.1%) and a 3.8% increase in adjusted profit before tax to £127.2m, reflecting resilience despite challenging market conditions and weak demand in some product areas. The company maintained operating margins at 15.7% through cost controls and raised its full-year dividend by 2.5%, while projecting steady revenue growth for FY26. Management targets long-term high single-digit growth and over 20% margins, driven by new product launches, productivity gains, and a £20m payroll reduction.

Analysis

Renishaw (LON:RSW) demonstrated operational resilience in its fiscal 2025 results, achieving record revenue of £713m, a 3.1% year-over-year increase, amidst challenging market conditions. While adjusted profit before tax grew 3.8% to £127.2m, statutory profit declined 3.7% to £118m due to one-off costs associated with portfolio restructuring, a critical distinction for evaluating core performance. The company successfully maintained stable operating margins at 15.7% by implementing cost controls that offset inflationary pressures. Segment performance was mixed; the core Manufacturing Technologies division grew 3.6%, but this was tempered by persistent softness in additive manufacturing and a 3.8% decline in the Analytical Instruments and Medical Devices unit. The balance sheet remains robust, with cash climbing to £273.6m and a strong cash conversion rate of 91%, supporting a 2.5% increase in the full-year dividend to 78.1p. Management's guidance for FY26 projects steady revenue growth, with long-term ambitions for high single-digit growth and margin expansion above 20%, underpinned by new product launches and a planned £20m payroll reduction.

Key Decisions for Investors

• Given the steady performance, strong cash position, and increased dividend, investors may view Renishaw as a stable holding, with the company's ability to manage costs in an inflationary environment being a key positive.
• Monitor progress on the company's long-term targets, particularly the execution of the £20m payroll reduction and the market reception of new products, as these are the primary catalysts for achieving the guided margin expansion above 20%.
• Investors should scrutinize future segmental results for a turnaround in the underperforming additive manufacturing and analytical instruments divisions, as continued weakness in these areas could offset gains in the core metrology business and temper overall growth.